kpcczКомплексные проблемы сердечно-сосудистых заболеванийComplex Issues of Cardiovascular Diseases2306-12782587-9537Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”kpccz-391Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL STUDIESКОММЕНТАРИИ РЕЦЕНЗЕНТОВ. Медикаментозное сопровождение эндоваскулярного лечения пациентов с хроническими окклюзиями коронарных артерий: есть ли место для статинов?ГанюковВ. И.СуминА. Н.ФГБНУ «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний»Россия201827032018713637Copyright © Ганюков В.И., Сумин А.Н., 20182018Ганюков В.И., Сумин А.Н.Ганюков В.И., Сумин А.Н.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nii-kpssz.com/jour/article/view/391
/
ReferencesWang L, Peng P, Zhang O, Xu X, Yang S, Zhao Y, Zhou Y. High-dose statin pretreatment decreases periprocedural myocardial infarction and cardiovascular events in patients undergoing elective percutaneous coronary intervention: a meta-analysis of twenty-four randomized controlled trials. PLoS One. 2014;9(12):e113352. doi: 10.1371/journal.pone.0113352. eCollection 2014.Wang L, Peng P, Zhang O, Xu X, Yang S, Zhao Y, Zhou Y. High-dose statin pretreatment decreases periprocedural myocardial infarction and cardiovascular events in patients undergoing elective percutaneous coronary intervention: a meta-analysis of twenty-four randomized controlled trials. PLoS One. 2014;9(12):e113352. doi: 10.1371/journal.pone.0113352. eCollection 2014.Lu C, Jia H, Wang Z. High-dose atorvastatin reduces the risk of cardiovascular events in patients with percutaneous coronary intervention. Oncotarget. 2017;8(41):70356-70365. doi: 10.18632/oncotarget.19701.Lu C, Jia H, Wang Z. High-dose atorvastatin reduces the risk of cardiovascular events in patients with percutaneous coronary intervention. Oncotarget. 2017;8(41):70356-70365. doi: 10.18632/oncotarget.19701.Рагозина А.С. Оценка уровня кардиомаркёров и функционального состояния миокарда у пациентов с реканализацией хронических окклюзий коронарных артерий при применении нагрузочных доз аторвастатина. Комплексные проблемы сердечно-сосудистых заболеваний. 2018; 7(1): 29-37.Рагозина А.С. Оценка уровня кардиомаркёров и функционального состояния миокарда у пациентов с реканализацией хронических окклюзий коронарных артерий при применении нагрузочных доз аторвастатина. Комплексные проблемы сердечно-сосудистых заболеваний. 2018; 7(1): 29-37.Patel VG, Brayton K, Tamayo A, et al. Incidence of angiographic success and procedural complications in patients undergoing percutaneous coronary chronic total occlusion interventions: a weighted metaanalysis of 18,061 patients from 65 studies. J Am Coll Cardiol Intv 2013;6:128–36.Patel VG, Brayton K, Tamayo A, et al. Incidence of angiographic success and procedural complications in patients undergoing percutaneous coronary chronic total occlusion interventions: a weighted metaanalysis of 18,061 patients from 65 studies. J Am Coll Cardiol Intv 2013;6:128–36.Danek B.A., Karatasakis A., Tajti P., et al. Incidence, Treatment, and Outcomes of Coronary Perforation During Chronic Total Occlusion Percutaneous Coronary Intervention. Am J Cardiol 2017;120:1285–1292.Danek B.A., Karatasakis A., Tajti P., et al. Incidence, Treatment, and Outcomes of Coronary Perforation During Chronic Total Occlusion Percutaneous Coronary Intervention. Am J Cardiol 2017;120:1285–1292.6. Lo N., Michael T.T., Moin D., Patel V.G., Alomar M., Papayannis A., Cipher D., Abdullah S.M., Banerjee S., Brilakis E.S. Periprocedural Myocardial Injury in Chronic Total Occlusion Percutaneous Interventions A Systematic Cardiac Biomarker Evaluation Study. Journal of the American College of Cardiology. 2014; 7(1): 47-54.6. Lo N., Michael T.T., Moin D., Patel V.G., Alomar M., Papayannis A., Cipher D., Abdullah S.M., Banerjee S., Brilakis E.S. Periprocedural Myocardial Injury in Chronic Total Occlusion Percutaneous Interventions A Systematic Cardiac Biomarker Evaluation Study. Journal of the American College of Cardiology. 2014; 7(1): 47-54.Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Glob Heart. 2012 Dec;7(4):275-95.Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Glob Heart. 2012 Dec;7(4):275-95.Allman KC, Shaw LJ, Hachamovitch R, et al. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol. 2002 Apr 3;39(7):1151-8.Allman KC, Shaw LJ, Hachamovitch R, et al. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol. 2002 Apr 3;39(7):1151-8.Zhang Q, Hu J, Yang ZK, et al. Correlates and outcomes related to periprocedural myocardial injury during percutaneous coronary intervention for chronic total occlusion: Results from a prospective, single center PCI registry. Catheter Cardiovasc Interv. 2016 Mar;87 Suppl 1:616-23.Zhang Q, Hu J, Yang ZK, et al. Correlates and outcomes related to periprocedural myocardial injury during percutaneous coronary intervention for chronic total occlusion: Results from a prospective, single center PCI registry. Catheter Cardiovasc Interv. 2016 Mar;87 Suppl 1:616-23.Kim J., Kim B, Kim S, et al. Incidence, predicting factors, and clinical outcomes of periprocedural myocardial infarction after percutaneous coronary intervention for chronic total occlusion in the era of new-generation drug-eluting stents. Catheter Cardiovasc Interv. 2017;1–9.Kim J., Kim B, Kim S, et al. Incidence, predicting factors, and clinical outcomes of periprocedural myocardial infarction after percutaneous coronary intervention for chronic total occlusion in the era of new-generation drug-eluting stents. Catheter Cardiovasc Interv. 2017;1–9.Morino Y, Abe M, Morimoto T, et al., J-CTO Registry Investigators. Predicting successful guidewire crossing through chronic total occlusion of native coronary lesions within 30 minutes: the J-CTO (Multicenter CTO Registry in Japan) score as a difficulty grading and time assessment tool. J Am Coll Cardiol Intv 2011;4:213–21.Morino Y, Abe M, Morimoto T, et al., J-CTO Registry Investigators. Predicting successful guidewire crossing through chronic total occlusion of native coronary lesions within 30 minutes: the J-CTO (Multicenter CTO Registry in Japan) score as a difficulty grading and time assessment tool. J Am Coll Cardiol Intv 2011;4:213–21.
The authors declare that there are no conflicts of interest present.